Prevail Therapeutics Inc.

(NASDAQ GS: PRVL)

Rigrodsky Law, P.A. is investigating Prevail Therapeutics Inc. (“Prevail”) regarding possible breaches of fiduciary duties and other violations of law related to Previal's agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, Prevail’s shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.

Join This Action

First Name*

Last Name*

Email Address*

Mailing Address*

City*

State/Province*

Zip/Postal Code*

Phone*

Number of Shares Purchased

Date(s) Shares Purchased

Purchase Price Per Share

Number of Shares Sold

Date(s) Shares Sold

Sale Price Per Share

Comments

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Select files

By signing and clicking the Submit button below, I hereby execute the Retention Agreement and, upon execution of the Retention Agreement by Rigrodsky Law, P.A., retain Rigrodsky Law, P.A. to bring a lawsuit on my behalf pursuant to the terms set forth in the Retention Agreement, which is incorporated herein by reference.*

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 01/21/2021

X Code

* Indicates a required field.